Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women

21. mars 2017 oppdatert av: GlaxoSmithKline

A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis

This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

515

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Aalst, Belgia, 9300
        • GSK Investigational Site
      • Brasschaat, Belgia, 2930
        • GSK Investigational Site
      • Bruxelles, Belgia, 1200
        • GSK Investigational Site
      • Gent, Belgia, 9000
        • GSK Investigational Site
    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • GSK Investigational Site
      • Toronto, Ontario, Canada, M5G 1X5
        • GSK Investigational Site
    • Quebec
      • Sainte-Foy, Quebec, Canada, G1V 4G2
        • GSK Investigational Site
      • Sherbrooke, Quebec, Canada, J1H 5N4
        • GSK Investigational Site
      • Moscow, Den russiske føderasjonen, 101000
        • GSK Investigational Site
      • Moscow, Den russiske føderasjonen, 111538
        • GSK Investigational Site
      • Moscow, Den russiske føderasjonen, 117152
        • GSK Investigational Site
      • Perm, Den russiske føderasjonen, 614107
        • GSK Investigational Site
      • St. Petersburgh, Den russiske føderasjonen, 192242
        • GSK Investigational Site
      • Manila, Filippinene, 1000
        • GSK Investigational Site
      • Quezon, City, Filippinene, 1104
        • GSK Investigational Site
    • Alabama
      • Fairhope, Alabama, Forente stater, 36532
        • GSK Investigational Site
      • Mobile, Alabama, Forente stater, 36608
        • GSK Investigational Site
      • Montgomery, Alabama, Forente stater, 36106
        • GSK Investigational Site
    • Arkansas
      • Little Rock, Arkansas, Forente stater, 72205
        • GSK Investigational Site
    • California
      • Arcadia, California, Forente stater, 91007
        • GSK Investigational Site
      • Glendale, California, Forente stater, 91206
        • GSK Investigational Site
      • Laguna Hills, California, Forente stater, 92653
        • GSK Investigational Site
      • Pasadena, California, Forente stater, 91105
        • GSK Investigational Site
    • Florida
      • Boca Raton, Florida, Forente stater, 33067
        • GSK Investigational Site
      • Melbourne, Florida, Forente stater, 32901
        • GSK Investigational Site
      • Miami, Florida, Forente stater, 33143
        • GSK Investigational Site
      • West Palm Beach, Florida, Forente stater, 33409
        • GSK Investigational Site
    • Illinois
      • Chicago, Illinois, Forente stater, 60637
        • GSK Investigational Site
    • Kansas
      • Kansas City, Kansas, Forente stater, 66160
        • GSK Investigational Site
    • Maryland
      • Baltimore, Maryland, Forente stater, 21229-5299
        • GSK Investigational Site
    • Michigan
      • Royal Oak, Michigan, Forente stater, 48073
        • GSK Investigational Site
    • New York
      • Mineola, New York, Forente stater, 11501
        • GSK Investigational Site
      • New Hyde Park, New York, Forente stater, 11040
        • GSK Investigational Site
      • New York, New York, Forente stater, 10038
        • GSK Investigational Site
    • North Carolina
      • Winston-Salem, North Carolina, Forente stater, 27103
        • GSK Investigational Site
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45208
        • GSK Investigational Site
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73104
        • GSK Investigational Site
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22908
        • GSK Investigational Site
      • Winchester, Virginia, Forente stater, 22601
        • GSK Investigational Site
    • Washington
      • Seattle, Washington, Forente stater, 98195
        • GSK Investigational Site
      • Kwun Tong, Hong Kong
        • GSK Investigational Site
      • Pokfulam, Hong Kong
        • GSK Investigational Site
      • Shatin, New Territories, Hong Kong
        • GSK Investigational Site
      • Sheung Shui, New Territories, Hong Kong
        • GSK Investigational Site
      • Lahore, Pakistan
        • GSK Investigational Site
      • Badalona, Spania, 08916
        • GSK Investigational Site
      • Barcelona, Spania, 08025
        • GSK Investigational Site
      • Barcelona, Spania, 08035
        • GSK Investigational Site
      • Barcelona, Spania, 08003
        • GSK Investigational Site
      • La Coruña, Spania, 15006
        • GSK Investigational Site
      • Mataro, Spania, 08034
        • GSK Investigational Site
      • Pamplona, Spania, 31008
        • GSK Investigational Site
      • Santiago de Compostela, Spania, 15706
        • GSK Investigational Site
      • Bangkok, Thailand
        • GSK Investigational Site
      • Brno, Tsjekkisk Republikk, 625 00
        • GSK Investigational Site
      • Jihlava, Tsjekkisk Republikk, 586 01
        • GSK Investigational Site
      • Olomouc, Tsjekkisk Republikk, 775 20
        • GSK Investigational Site
      • Pardubice, Tsjekkisk Republikk, 532 03
        • GSK Investigational Site
      • Praha 2, Tsjekkisk Republikk, 128 51
        • GSK Investigational Site
      • Praha 5, Tsjekkisk Republikk, 150 08
        • GSK Investigational Site
    • Baden-Wuerttemberg
      • Freiburg, Baden-Wuerttemberg, Tyskland, 79110
        • GSK Investigational Site
    • Hessen
      • Marburg, Hessen, Tyskland, 35043
        • GSK Investigational Site
    • Mecklenburg-Vorpommern
      • Neubrandenburg, Mecklenburg-Vorpommern, Tyskland, 17036
        • GSK Investigational Site
      • Rostock, Mecklenburg-Vorpommern, Tyskland, 18059
        • GSK Investigational Site
      • Schwerin, Mecklenburg-Vorpommern, Tyskland, 19055
        • GSK Investigational Site
      • Wismar, Mecklenburg-Vorpommern, Tyskland, 23966
        • GSK Investigational Site
    • Rheinland-Pfalz
      • Ludwigshafen, Rheinland-Pfalz, Tyskland, 67063
        • GSK Investigational Site
    • Saarland
      • Homburg, Saarland, Tyskland, 66421
        • GSK Investigational Site
    • Sachsen-Anhalt
      • Halle, Sachsen-Anhalt, Tyskland, 06120
        • GSK Investigational Site
    • Schleswig-Holstein
      • Kiel, Schleswig-Holstein, Tyskland, 24105
        • GSK Investigational Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion criteria:

  • History of PONV (postoperative nausea and vomiting) and/or motion sickness.
  • Have not smoked for the last 6 months.
  • Having certain abdominal, breast, thyroid or shoulder surgery.

Exclusion criteria:

  • Pregnant or breastfeeding.
  • Have certain pre-existing medical conditions or take certain medications.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of participants who achieved a complete response
Tidsramme: Up to 24 hours
Complete response defined as no vomiting or retching and no rescue therapy during the first 24 hours following placement of the last suture/staple. Vomiting defined as the forceful expulsion of gastrointestinal contents through the mouth or nose. Retching defined as the labored, spasmodic, rhythmic contraction of the respiratory and abdominal muscles in an attempt to vomit that is not productive of gastrointestinal contents (also known as "dry heaves"). Study participants who receive antiemetic rescue medication(s) during the initial 24 hours was considered treatment failures.
Up to 24 hours

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The severity of nausea experienced by participants in each cohort during the 2, 6, 24 and 48 hour periods, as assessed by an 11-point, linear, numerical rating scale referred to as a "0-10 Likert scale"
Tidsramme: Up to 48 hours
Nausea is defined as a subjectively unpleasant sensation associated with the awareness of the urge to vomit; the desire to vomit without the presence of expulsive muscular movements. Each participant completed a Likert scale at 2, 6, 24 and 48 hours after placement of the last suture/staple. The Likert scale used a range of 0-10, where 0 = no nausea and 10 = nausea as bad as it could be.
Up to 48 hours
The severity of nausea experienced by participants in each cohort during the 2, 6, 24 and 48 hour periods, as assessed by a categorical scale (none, mild, moderate or severe), as defined in the protocol
Tidsramme: Up to 48 hours
Nausea is defined as a subjectively unpleasant sensation associated with the awareness of the urge to vomit; the desire to vomit without the presence of expulsive muscular movements. Each participant completed a categorical scale at 2, 6, 24 and 48 hours after placement of the last suture/staple. In the categorical scale, each participant asked to rate the severity of nausea as, none: no nausea, mild: queasiness/upset stomach that is manageable and minimally (if at all) affects daily activities, moderate: increased queasiness, sometimes with the feeling of having to vomit (but not vomiting), that has a significant negative effect on daily activities (for example, being unable to work, eat and drink, prepare food, care for children or others), severe: feeling sick and vomiting or feeling like you are going to vomit, and unable to perform most daily activities.
Up to 48 hours
Number of participants with first emetic event
Tidsramme: Up to 48 hours
Up to 48 hours
Number of participants with first antiemetic rescue medication
Tidsramme: Up to 48 hours
Up to 48 hours
Participant satisfaction with the prophylactic antiemetic regimens, as assessed by participant satisfaction assessments in the participant diary
Tidsramme: Up to 48 hours
Up to 48 hours
Participant willingness of participants to use the same treatment regimen for future surgical procedures, as assessed by participant satisfaction assessments in the participant diary
Tidsramme: Up to 48 hours
Up to 48 hours
Number of participants with chemistry data outside the reference range
Tidsramme: Up to 48 hours
Up to 48 hours
Number of participants with hematology data outside the reference range
Tidsramme: Up to 48 hours
Up to 48 hours
Safety and tolerability of the antiemetic regimens, assessed by clinical observation (including time to awakening from anesthesia, defined as ability to respond to a verbal command)
Tidsramme: Up to 24 hours
Up to 24 hours
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Tidsramme: Up to Days 6-14 visit
An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition. Refer to the general AE/SAE module for a list of AEs and SAEs.
Up to Days 6-14 visit

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. mars 2006

Primær fullføring (Faktiske)

1. juli 2006

Studiet fullført (Faktiske)

1. juli 2006

Datoer for studieregistrering

Først innsendt

2. juni 2006

Først innsendt som oppfylte QC-kriteriene

2. juni 2006

Først lagt ut (Anslag)

6. juni 2006

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

23. mars 2017

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. mars 2017

Sist bekreftet

1. mars 2017

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

Ja

IPD-planbeskrivelse

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Studiedata/dokumenter

  1. Datasettspesifikasjon
    Informasjonsidentifikator: NKT102552
    Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  2. Datasett for individuell deltaker
    Informasjonsidentifikator: NKT102552
    Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  3. Annotert saksrapportskjema
    Informasjonsidentifikator: NKT102552
    Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  4. Skjema for informert samtykke
    Informasjonsidentifikator: NKT102552
    Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  5. Studieprotokoll
    Informasjonsidentifikator: NKT102552
    Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  6. Klinisk studierapport
    Informasjonsidentifikator: NKT102552
    Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  7. Statistisk analyseplan
    Informasjonsidentifikator: NKT102552
    Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere